CRNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Crinetics Pharmaceuticals's change in working capital for the quarter that ended in Mar. 2024 was $2.69 Mil.
Crinetics Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2023 was $8.04 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
The historical data trend for Crinetics Pharmaceuticals's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Working Capital | Get a 7-Day Free Trial | -2.13 | 0.38 | 1.10 | 18.61 | 8.04 |
Crinetics Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Working Capital | Get a 7-Day Free Trial | -0.69 | -4.42 | 4.85 | 8.30 | 2.69 |
Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.42 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC
Consolidated Statements of Cash Flows | Fiscal Years Ended | January 31, | (Amounts in millions) |
Cash flows from operating activities: | 2014 | 2013 | 2012 |
Changes in certain assets and liabilities, net of effects of acquisitions: | |||
Receivables, net | (566) | (614) | (796) |
Inventories | (1,667) | (2,759) | (3,727) |
Accounts payable | 531 | 1,061 | 2,687 |
Accrued liabilities | 103 | 271 | (935) |
Accrued income taxes | (1,224) | 981 | 994 |
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen F. Betz | officer: Chief Scientific Officer | 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Dana Pizzuti | officer: Chief Development Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Marc Wilson | officer: See Remarks | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Richard Scott Struthers | director, officer: See Remarks | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Alan Seth Krasner | officer: Chief Medical Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Vivaldi Coelho Rogerio | director | 225 SECOND AVENUE, WALTHAM MA 02451 |
Jeff E. Knight | officer: Chief Operating Officer | CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Caren Deardorf | director | C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
James Hassard | officer: Chief Commercial Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Ajay Madan | officer: Chief Development Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121 |
Camille L Bedrosian | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By Marketwired • 08-10-2023
By GlobeNewswire GlobeNewswire • 02-10-2023
By sperokesalga sperokesalga • 05-10-2023
By sperokesalga sperokesalga • 06-12-2023
By GlobeNewswire • 11-10-2023
By GuruFocus Research • 11-04-2023
By sperokesalga sperokesalga • 05-04-2023
By Marketwired • 08-08-2023
By GuruFocus Research • 12-29-2023
By sperokesalga sperokesalga • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.